Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G, Ricafort R, Heenen D, Bassan A, Berntgen M, Bird N, Bleickardt E, Bouchkouj N, Bross P, Brownstein C, Cohen SB, de Rojas T, Ehrlich L, Fox E, Gottschalk S, Hanssens L, Hawkins DS, Horak ID, Taylor DH, Johnson C, Karres D, Ligas F, Ludwinski D, Mamonkin M, Marshall L, Masouleh BK, Matloub Y, Maude S, McDonough J, Minard-Colin V, Norga K, Nysom K, Pappo A, Pearce L, Pieters R, Pule M, Quintás-Cardama A, Richardson N, Schüßler-Lenz M, Scobie N, Sersch MA, Smith MA, Sterba J, Tasian SK, Weigel B, Weiner SL, Zwaan CM, Lesa G, Vassal G. Pearson AD, et al. Among authors: mamonkin m. Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25. Eur J Cancer. 2022. PMID: 34840026 Free article. Review.
Analysis of CAR-Mediated Tonic Signaling.
Calderon H, Mamonkin M, Guedan S. Calderon H, et al. Among authors: mamonkin m. Methods Mol Biol. 2020;2086:223-236. doi: 10.1007/978-1-0716-0146-4_17. Methods Mol Biol. 2020. PMID: 31707680
Engineered off-the-shelf therapeutic T cells resist host immune rejection.
Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. Mo F, et al. Among authors: mamonkin m. Nat Biotechnol. 2021 Jan;39(1):56-63. doi: 10.1038/s41587-020-0601-5. Epub 2020 Jul 13. Nat Biotechnol. 2021. PMID: 32661440 Free PMC article.
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.
Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Steffin DHM, et al. Among authors: mamonkin m. Blood. 2022 Jul 7;140(1):16-24. doi: 10.1182/blood.2022015728. Blood. 2022. PMID: 35325065 Free PMC article.
CD7 CAR: sword and shield.
Velasquez MP, Mamonkin M. Velasquez MP, et al. Among authors: mamonkin m. Blood. 2022 Jul 28;140(4):293-294. doi: 10.1182/blood.2022016595. Blood. 2022. PMID: 35900789 Free PMC article. No abstract available.
Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, Patil SL, Khanlari M, Inaba H, Klco JM, Mullighan CG, Krenciute G, Chockley PJ, Naik S, Langfitt DM, Mamonkin M, Obeng EA, Thomas PG, Gottschalk S, Velasquez MP. Freiwan A, et al. Among authors: mamonkin m. Blood. 2022 Dec 22;140(25):2684-2696. doi: 10.1182/blood.2021015020. Blood. 2022. PMID: 35914226 Free PMC article.
45 results